Trials / Completed
CompletedNCT00741910
Extension Study of Semapimod 60 mg IV x 3 Days
Extension Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study CNI-1493-CD06 is an open, single-arm extension studies to CD03 and CD05. CDAI is the only efficacy measure assessed in this study. The safety of multiple courses of semapimod is to be determined by the incidence of clinical and laboratory adverse events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semapimod | semapimod IV 60 mg x 3 days q 6 - 10 weeks |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2006-06-01
- Completion
- 2006-06-01
- First posted
- 2008-08-26
- Last updated
- 2023-11-18
Locations
8 sites across 4 countries: United States, Germany, Israel, Netherlands
Source: ClinicalTrials.gov record NCT00741910. Inclusion in this directory is not an endorsement.